ArticlemBio2021
Antifungal Liposomes Directed by Dectin-2 Offer a Promising Therapeutic Option for Pulmonary Aspergillosis.
Article in mBio, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Edible Fungal Polysaccharide-Liposome: Interfacial Interactions, Structure-Function Relationship, and Emerging Application in Oral Delivery and Functional Foods.International journal of molecular sciences · 2026Review
- Polyphenol-Loaded Liposomal Nanocarriers fromMolecules (Basel, Switzerland) · 2026Article
- Human Dectin-1- and Dectin-2-targeted DectiSomes are effective against diverse pathogenic fungi.Antimicrobial agents and chemotherapy · 2026Article
- Altering the ligand specificity of DectiSomes.The Journal of biological chemistry · 2025Article
- Siglec-targeted liposomes to identify sialoglycans present on fungal pathogens.Antimicrobial agents and chemotherapy · 2025Article
- Poloxamer 188 stabilized poly (ε-caprolactone) microspheres of voriconazole for targeting pulmonary aspergillosis.Therapeutic delivery · 2025Article
- Cell aggregation mediated bymSphere · 2024Article
- The pathobiology of human fungal infections.Nature reviews. Microbiology · 2024Review
- All hands on Dec: Treating cryptococcosis with dectin decorated liposomes loaded with antifungals.iScience · 2024Article
- Dectin-3-targeted antifungal liposomes efficiently bind and kill diverse fungal pathogens.Molecular microbiology · 2023Article
- Fungal Drug Response and Antimicrobial Resistance.Journal of fungi (Basel, Switzerland) · 2023Review
- DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs.Advanced drug delivery reviews · 2023Review
- Tackling the emerging threat of antifungal resistance to human health.Nature reviews. Microbiology · 2022Review
- DectiSomes: Glycan Targeting of Liposomal Drugs Improves the Treatment of Disseminated Candidiasis.Antimicrobial agents and chemotherapy · 2022Article
- DC-SIGN targets amphotericin B-loaded liposomes to diverse pathogenic fungi.Fungal biology and biotechnology · 2021Article
- Aiming for a bull's-eye: Targeting antifungals to fungi with dectin-decorated liposomes.PLoS pathogens · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Invasive fungal diseases cause millions of deaths each year. There are currently approximately 300,000 acute cases of aspergillosis, most of which result from a pulmonary infection of immunocompromised patients by the common soil organism and opportunistic pathogen
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.